Designing and Executing Basket Trials Using Genetic Markers

Introduction to Basket Trials in Oncology

Basket trials represent a paradigm shift in oncology trial design. Instead of recruiting patients based solely on tumor histology (e.g., lung, breast, colorectal), basket trials enroll patients who share a common genetic alteration across multiple tumor types. For example, a trial may test a BRAF inhibitor in any solid tumor harboring a BRAF V600E mutation, regardless of whether it originated in the thyroid, lung, or colon.

This approach supports the concept of tumor-agnostic therapy—where the drug’s indication is defined by the biomarker rather than the cancer’s site of origin. The FDA has already approved multiple tumor-agnostic indications, such as pembrolizumab for microsatellite instability-high (MSI-H) tumors and larotrectinib for NTRK fusions.

Basket trials are especially valuable for rare mutations, where traditional histology-specific trials would take years to accrue enough patients. By pooling patients across cancers, basket trials accelerate development timelines and enable smaller, more focused studies.

Regulatory Perspective on Basket Trials

Regulatory agencies recognize the value of basket trials but expect robust scientific rationale and statistical design. The FDA’s 2019 guidance on enrichment strategies emphasizes that basket trials should pre-specify the biomarker, inclusion/exclusion criteria, and statistical plan for each tumor type cohort. If efficacy varies significantly between histologies, tumor-specific labeling may be required rather than a broad tumor-agnostic claim.

The EMA requires similar rigor and recommends using adaptive statistical models to address variability in treatment effect. Under the new EU Clinical Trials Regulation (CTR), multinational basket trials must clearly define how genetic testing is performed and validated across all participating sites.

Examples of regulatory success include the Vitrakvi (larotrectinib) approval based on pooled efficacy data across 17 tumor types with NTRK fusions, and the approval of entrectinib with combined data from multiple basket studies targeting ROS1-positive NSCLC and NTRK fusion-positive tumors.

Designing a Basket Trial: Step-by-Step

Designing a basket trial requires careful alignment between scientific, regulatory, and operational teams. The typical workflow includes:

1. Identify the Target Genetic Marker: Select a biomarker with strong preclinical and/or early clinical evidence of drug sensitivity.
2. Validate the Diagnostic Assay: Use an FDA-approved or analytically validated NGS or PCR-based assay to confirm biomarker status. Parameters like LOD (e.g., 1% VAF for ctDNA detection) and LOQ must be pre-specified.
3. Define Cohorts: Create separate cohorts for each tumor type or relevant clinical context. Example: Cohort A—BRAF V600E colorectal cancer; Cohort B—BRAF V600E thyroid cancer.
4. Statistical Plan: Decide whether each cohort will be analyzed independently or in a pooled manner. Bayesian hierarchical models can borrow information across cohorts to improve power.
5. Adaptive Features: Include interim analyses to drop non-responsive cohorts or expand promising ones.

A dummy table for a hypothetical BRAF basket trial could look like this:

Operational Considerations: Biomarker Testing and Turnaround

Fast and accurate biomarker testing is critical to basket trial success. A delay in obtaining NGS results can lead to patient drop-off or missed treatment windows. Many sponsors use central laboratories for uniformity, but decentralized testing at local labs may be necessary for rare mutations with urgent treatment needs. In either case, cross-validation of local and central assays is essential, with ≥90% concordance required for regulatory acceptability.

Informed consent must explicitly describe genetic testing, data sharing, and potential incidental germline findings. Moreover, trial teams should prepare SOPs for genetic data handling in compliance with GDPR in the EU and HIPAA in the US.

For best practices in trial SOP creation, resources from PharmaSOP.in offer practical templates adapted to biomarker-driven studies.

Real-World Example: NTRK Fusion Basket Trials

Larotrectinib’s basket trials are a textbook example. By enrolling patients with NTRK fusions across 17 tumor types and pooling the data, the sponsor demonstrated a 75% ORR with durable responses, leading to tumor-agnostic approval. The trial incorporated rigorous confirmatory testing of NTRK fusion status, standardized imaging assessments, and patient-reported outcomes as secondary endpoints.

One key regulatory takeaway: durability of response was critical for approval, as median duration exceeded 9 months in most tumor types. This long-term follow-up data was essential to justify a tumor-agnostic claim rather than multiple tumor-specific approvals.

Conclusion: The Future of Basket Trials

Basket trials have transformed oncology drug development, enabling faster access to targeted therapies for patients with rare genetic alterations. Success hinges on selecting robust biomarkers, validating assays, designing statistically sound and adaptive trials, and meeting regulatory expectations for multi-cohort data interpretation.

As molecular profiling becomes standard of care, basket trials will likely expand beyond oncology into rare genetic diseases, leveraging the same precision medicine principles. The ability to demonstrate benefit across diverse patient populations, regardless of tumor origin, positions basket trials as a cornerstone of next-generation clinical research.